GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France

Core Viewpoint - GenSight Biologics has received compassionate use authorization from the French medicines safety agency ANSM for its innovative gene therapies targeting retinal neurodegenerative diseases and central nervous system disorders [1] Company Summary - GenSight Biologics is a biopharma company focused on developing and commercializing gene therapies [1] - The company is listed on Euronext under the ticker SIGHT and is eligible for PEA-PME [1] Regulatory Update - The French medicines safety agency ANSM has granted compassionate use authorization (Autorisation d'Accès Compassionnel, or AA) for GenSight's therapies [1]